|Mr. Fuad El-Hibri||Founder & Exec. Chairman||1.03M||1.71M||1958|
|Mr. Daniel J. Abdun-Nabi||CEO & Director||1.63M||2.63M||1955|
|Mr. Robert G. Kramer Sr.||Pres & COO||881.34k||N/A||1957|
|Mr. Atul Saran||Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec.||659.71k||N/A||1973|
|Mr. Adam R. Havey||Exec. VP of Bus. Operations||722k||264.54k||1971|
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Emergent BioSolutions Inc.’s ISS Governance QualityScore as of February 1, 2019 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 7; Compensation: 2.